The Coronavirus Disease 2019 (COVID-19) pandemic led to the swift development of multiple vaccinations. Vaccine side effects were well-documented in the healthy adult cohort and included fever and lymphadenopathy, however, side effects in the pediatric immunocompromised population have not been reported. This retrospective study investigated vaccine-eligible children and adolescent young adult oncology patients 12 to 35 years old. We found uncommon, mild, and self-limiting side effects among pediatric cancer patients and survivors. This data will help guide pediatric and AYA oncologists in providing anticipatory guidance and serve as a guide to managing lymphadenopathy as a potential confounder of malignancy.

Creator

• Belsky, J.

• Carroll, Whitney R.

• Xu, Guang

• Jacob, S.

Publisher

• Wolters Kluwer Health, Inc.

Language

• English

Identifier

• DOI: 10.1097/MPH.0000000000002621

• PMID: 36716067

• PMCID: PMC10025933

Keyword

• pediatric oncology

• supportive care

• COVID-19

• vaccination

Date created

• 2023

Related URL

• Available from PubMed:  https://pubmed.ncbi.nlm.nih.gov/36716067/

• Available from PubMed Central:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025933/

• Available from publisher:  https://journals.lww.com/jpho-online/Fulltext/2023/03000/Side_Effects_With_a_Focus_on_Lymphadenopathy.7.aspx

• Available from library catalog:  https://marianunivindianapolis.on.worldcat.org/oclc/9753631805

Resource type

• Article

Source

• Journal of Pediatric Hematology/Oncology (Vol.45, No.2)

Rights statement

• http://rightsstatements.org/vocab/InC/1.0/